Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
It has been estimated that approximately 8.4% of the world population currently live with diabetes mellitus and type 2 diabetes is the most common form.Type 2 diabetes increases the risk of complications such as heart attacks, blindness, amputations and kidney failure.Glucagon like Peptide-1 (GLP-1) is an effective insulinotropic agent and therefore its effects on insulin secretion have been greatly examined for more than two decades.It is a polypeptide hormone secreted by the intestinal L-cells into the blood in response to food uptake.GLP-1 has a very short half-life in vivo due to the rapid proteolytic degradation by Dipeptidyl Peptidase IV (DPP-IV).Therefore DPP-IV resistant GLP-1 analogues, Exenatide and Liraglutide, have been developed and are currently being used in the treatment of type 2 diabetes.GLP-1 agonist functions by binding to its receptor, GLP1R, on the cell surface.The GLP-1R belongs to the class B peptide receptor family based on its structure and function.The binding of GLP-1 to its receptor results in activation of Gαs coupled adenylyl cyclase and the production of cyclic Adenosine Monophosphate (cAMP), which enhances glucose-induced insulin secretion.Continuous GLP-1R activation also causes insulin secretion and pancreatic islet β-cell proliferation and neogenesis.The GLP-1R is internalised following its activation, which regulates the biological responsiveness of the receptor.Structurally the GLP-1R contains a large N-terminal extracellular domain (TM1-TM7) joined by three intracellular loops (ICL1, ICL2, ICL3) and three extracellular loops (ECL1, ECL2, ECL3), and an intracellular C-terminal domain.These domains play critical roles in GLP-1R trafficking to the cell surface, and also in agonist dependent activation and internalisation of the receptor.This review is focused on type 2 diabetes, its treatment with GLP-1, GLP-1R structure and function, and the physiological affects resulting from GLP-1R activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intracellular Functions of N-Linked Glycans
Helenius, A., & Aebi, A. M. (2001) · Science · doi:10.1126/science.291.5512.2364 · Cited by 2,405 · cited 1×
“Terminal glucose residues are cleaved by glucosidases and oligomannoses are formed (Figure 12A) [189].”
BackgroundHu, F. B. (2011) · Diabetes Care · doi:10.2337/dc11-0442 · Cited by 1,954 · cited 1×
“Diet, sedentary lifestyle and genetics all play a role in the development of type 2 diabetes [7,25,26].”
BackgroundIslet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“However, the effects seem to subside with continuous administration [66,120].”
BackgroundReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 2×
“However, it was noted that glucose administered orally promoted a significantly greater insulin response than glucose administered intravenously (Figure 2), although plasma glucose levels were the same [38-40].”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“This strongly suggests a role for incretin hormones or their actions in the treatment of type 2 diabetes [39,52-55].”
BackgroundMolecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes
Muoio, D. M., & Newgard, C. B. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2327 · Cited by 1,177
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 1×
“Exenatide is a peptide found within the salivary glands of the Gila monster lizard and has 52% sequence homology to GLP-1 [116].”
Background
Cited by
Recent advances in understanding the role of glucagon-like peptide 1
Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66
Nguyen, T. T. N., Choi, H., & Jun, H.-S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00090 · Cited by 34
“As GLP-1 receptor agonists reduce food intake (Ronveaux et al., 2014; Wan et al., 2017), the same amount of food as that consumed by dulaglutide-treated group was provided to the control vehicle-treated group.”
BackgroundThompson, A., Stephens, J. W., Bain, S. C., & Kanamarlapudi, V. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154229 · Cited by 19
“Both GLP-1R agonists, liraglutide (a DPP-IV resistant GLP-1) and exenatide (a synthetic version of exendin-4), are currently in use as drugs for the treatment of patients with type 2 diabetes [14–16].”
BackgroundInfluentialMechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists
Reed, J., Kanamarlapudi, V., & Bain, S. (2018) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000147 · Cited by 16
Metadata
- Authors
- Aiysha Thompson, K.
- Venue
- Clinical & Experimental Pharmacology
- Publisher
- OMICS Publishing Group
- Published
- 2013
- Volume
- 03
- Issue
- 04
- ISSN
- 2161-1459 (ISSN-L)
- OpenAlex
- W2168620887
- Cited by
- 33
- References
- 47
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling. https://app.cochat.ai/papers/10.4172/2161-1459.1000138
- The paper
- Aiysha Thompson, K. (2013). Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling. Clinical & Experimental Pharmacology. https://doi.org/10.4172/2161-1459.1000138
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.